Birchview Capital, LP Buys Cullinan Oncology Inc, ACADIA Pharmaceuticals Inc, Nektar Therapeutics, Sells Aspira Womens Health Inc, Oxford Immunotec Global PLC, Odonate Therapeutics Inc

• New Purchases: CGEM, NKTR, AWH, ALKS, LSF, ARQT, PTGX, TXMD, CNCE,
• Added Positions: ACAD, ALBO, KPTI, BLUE, KALV, PROG,
• Reduced Positions: STOK,
• Sold Out: CUL1, OXFD, ODT,

For the details of Birchview Capital, LP's stock buys and sells, go to https://www.gurufocus.com/guru/birchview+capital%2C+lp/current-portfolio/portfolio

1. Bristol-Myers Squibb Company (BMY) - 794,186 shares, 36.21% of the total portfolio. Shares reduced by 0.03%
2. Accelerate Diagnostics Inc (AXDX) - 2,213,326 shares, 13.28% of the total portfolio. Shares added by 0.89%
3. Neurocrine Biosciences Inc (NBIX) - 80,200 shares, 5.63% of the total portfolio.
4. Quidel Corp (QDEL) - 58,644 shares, 5.42% of the total portfolio.
5. ACADIA Pharmaceuticals Inc (ACAD) - 177,000 shares, 3.30% of the total portfolio. Shares added by 73.53%

Birchview Capital, LP initiated holding in Cullinan Oncology Inc. The purchase prices were between $28 and $53.42, with an estimated average price of $40.59. The stock is now traded at around $27.660000. The impact to a portfolio due to this purchase was 1.81%. The holding were 60,114 shares as of 2021-03-31.

Birchview Capital, LP initiated holding in Nektar Therapeutics. The purchase prices were between $16.56 and $25.46, with an estimated average price of $20.78. The stock is now traded at around $18.980000. The impact to a portfolio due to this purchase was 1.33%. The holding were 92,000 shares as of 2021-03-31.

Birchview Capital, LP initiated holding in Aspira Womens Health Inc. The purchase prices were between $5.9 and $9.13, with an estimated average price of $7.36. The stock is now traded at around $5.110000. The impact to a portfolio due to this purchase was 0.5%. The holding were 103,104 shares as of 2021-03-31.

Birchview Capital, LP initiated holding in Alkermes PLC. The purchase prices were between $18.21 and $23.2, with an estimated average price of $20.46. The stock is now traded at around $22.260000. The impact to a portfolio due to this purchase was 0.47%. The holding were 35,000 shares as of 2021-03-31.

Birchview Capital, LP initiated holding in Laird Superfood Inc. The purchase prices were between $33.27 and $55.72, with an estimated average price of $42.69. The stock is now traded at around $31.760000. The impact to a portfolio due to this purchase was 0.38%. The holding were 14,000 shares as of 2021-03-31.

Birchview Capital, LP initiated holding in Protagonist Therapeutics Inc. The purchase prices were between $19.02 and $31.15, with an estimated average price of $25.32. The stock is now traded at around $30.470000. The impact to a portfolio due to this purchase was 0.19%. The holding were 10,000 shares as of 2021-03-31.

Birchview Capital, LP added to a holding in ACADIA Pharmaceuticals Inc by 73.53%. The purchase prices were between $25.02 and $54.99, with an estimated average price of $44.12. The stock is now traded at around $21.770000. The impact to a portfolio due to this purchase was 1.4%. The holding were 177,000 shares as of 2021-03-31.

Birchview Capital, LP added to a holding in Albireo Pharma Inc by 20.65%. The purchase prices were between $32.03 and $42.85, with an estimated average price of $36.93. The stock is now traded at around $29.900000. The impact to a portfolio due to this purchase was 0.48%. The holding were 111,000 shares as of 2021-03-31.

Birchview Capital, LP added to a holding in Karyopharm Therapeutics Inc by 22.34%. The purchase prices were between $9.85 and $17.69, with an estimated average price of $14.07. The stock is now traded at around $9.180000. The impact to a portfolio due to this purchase was 0.32%. The holding were 230,000 shares as of 2021-03-31.

Birchview Capital, LP added to a holding in bluebird bio Inc by 21.77%. The purchase prices were between $25.62 and $52.33, with an estimated average price of $38.14. The stock is now traded at around $30.320000. The impact to a portfolio due to this purchase was 0.29%. The holding were 75,500 shares as of 2021-03-31.

Birchview Capital, LP added to a holding in KalVista Pharmaceuticals Inc by 33.33%. The purchase prices were between $14.69 and $42.57, with an estimated average price of $26.54. The stock is now traded at around $26.060000. The impact to a portfolio due to this purchase was 0.19%. The holding were 40,000 shares as of 2021-03-31.

Birchview Capital, LP sold out a holding in Aspira Womens Health Inc. The sale prices were between $4.74 and $7.5, with an estimated average price of $5.93.

Birchview Capital, LP sold out a holding in Oxford Immunotec Global PLC. The sale prices were between $17.15 and $22.29, with an estimated average price of $21.65.

Birchview Capital, LP sold out a holding in Odonate Therapeutics Inc. The sale prices were between $3.09 and $27.39, with an estimated average price of $19.